Healthcare Services

Typhoid Vi Polysaccharide Vaccine Market Forecast with Key Trends

April 28, 2026April 30, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Typhoid Vi Polysaccharide Vaccine Market Grow Between 2026 And 2030?

The typhoid vi polysaccharide vaccine market has experienced substantial expansion in recent times. Projections indicate it will increase from $6.71 billion in 2025 to $7.92 billion by 2026, advancing at a compound annual growth rate (CAGR) of 18.1%. The market’s historical growth can be attributed to the broader implementation of national immunization schedules, a heightened understanding of typhoid prevention, the accessibility of polysaccharide vaccine formulations, an increase in public vaccination initiatives, and assistance from global health organizations.

The typhoid vi polysaccharide vaccine market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $15.51 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 18.3%. This projected growth during the forecast period stems from several factors, including an intensified focus on widespread immunization in areas where the disease is prevalent, an uptick in investments dedicated to vaccine production capabilities, the broader implementation of vaccination initiatives for adults, an increasing emphasis on vaccinations pertinent to travel, and the wider integration of enhanced vaccine storage solutions. Key trends foreseen for the forecast period encompass a rise in government-backed immunization initiatives, a heightened need for comprehensive pediatric vaccination coverage, a greater concentration on proactive healthcare strategies, the diversification of vaccine distribution through public-private partnerships, and a strengthened commitment to optimizing cold chain logistics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8313&type=smp

Which Major Drivers Are Influencing The Expansion Of The Typhoid Vi Polysaccharide Vaccine Market?

The increasing incidence of typhoid is anticipated to drive the expansion of the typhoid Vi polysaccharide vaccine market moving forward. Typhoid, a potentially fatal infection caused by *Salmonella Typhi* bacteria, typically spreads through tainted food or drinks. Factors contributing to this rise in typhoid cases include inadequate sanitation, unsafe water sources, rapid urban development, and heightened exposure to contaminated food and water. The typhoid Vi polysaccharide vaccine market addresses this issue by offering immunization to adults and children aged two years and older, thereby providing protective immunity against *Salmonella enterica* serovar Typhi and lessening the impact of typhoid fever in endemic areas. For instance, data released by the UK Health Security Agency in August 2024 indicated an increase in laboratory-confirmed symptomatic enteric fever cases across England, Wales, and Northern Ireland, with S. Typhi cases reaching 313, S. Paratyphi A reaching 135 cases, and S. Paratyphi B reaching 18 cases. Consequently, the escalating prevalence of typhoid is a key factor propelling the growth of the typhoid Vi polysaccharide vaccine market. The expansion of immunization initiatives is expected to stimulate the growth of the typhoid Vi polysaccharide vaccine market in the coming years. Immunization campaigns are defined as strategies for delivering one or more vaccines quickly to a large number of individuals at either a national or sub-national level. The surge in these campaigns is primarily fueled by an intensified public health focus on preventing typhoid in regions with high disease burden, alongside the imperative to reduce antimicrobial resistance through widespread vaccination. These growing immunization campaigns contribute to the typhoid Vi polysaccharide vaccine by enhancing vaccine awareness, improving accessibility, and increasing coverage, ultimately leading to a reduction in the incidence and transmission of typhoid fever. For example, in June 2023, the UK Health Security Agency, a government body based in the UK, reported that a total of 3,502,566 children, from Reception to Year 9, were vaccinated as part of the school-aged vaccination program during 2022–2023. Therefore, the increasing number of immunization campaigns is a significant driver for the growth of the typhoid Vi polysaccharide vaccine market.

How Is The Typhoid Vi Polysaccharide Vaccine Market Broken Down By Segment Categories?

The typhoid vi polysaccharide vaccine market covered in this report is segmented –

1) By Type: Child, Adult

2) By Route Of Administration: Oral, Parenteral

3) By Application: Government Institution, Private Sector, Other Applications

Subsegments:

1) By Child: Pediatric Formulations, Age-Specific Dosages

2) By Adult: Standard Adult Formulations, High-Risk Population Formulations

Which Trends Are Shaping The Typhoid Vi Polysaccharide Vaccine Market?

Major companies operating in the typhoid Vi polysaccharide vaccine market are strengthening their position through strategic investments, notably funding partnerships for next-generation vaccine delivery platforms, to accelerate innovation and expand global immunization reach. These collaborative investment initiatives, defining funding partnerships for advanced vaccine delivery platforms, aim to develop improved typhoid vaccination technologies, specifically needle-free, thermostable, and easy-to-administer formats. Such advancements are crucial for enhancing accessibility, coverage, and compliance in low-resource settings. For example, in August 2023, South Korea-based biotech company SK Bioscience, in collaboration with Australia-based Vaxxas, a specialist in needle-free vaccine delivery, secured AUD 0.0054 billion (USD 0.00367 billion) in funding from Wellcome, a UK-based charitable foundation. This funding is dedicated to developing a typhoid conjugate vaccine delivered via a needle-free high-density microarray patch (HD-MAP). This innovative solution features a micro-projection patch that obviates the need for traditional needles, offers thermostability crucial for distribution in regions with limited infrastructure, and holds the potential for simplified, pain-free administration, ultimately targeting improved global uptake of typhoid vaccination.

Which Players Are Present In The Typhoid Vi Polysaccharide Vaccine Market Space?

Major companies operating in the typhoid vi polysaccharide vaccine market are Sanofi S.A., Merck & Co. Inc., PT Bio Farma, Bharat Biotech International Limited, Bio-Med Pvt. Ltd., Hualan Biological Engineering Inc., Indian Immunologicals Limited, Serum Institute of India Limited, Biological E Limited, Panacea Biotec Limited, Zydus Lifesciences Limited, Beijing Minhai Biotechnology Co. Ltd., Lanzhou Institute of Biological Products Co. Ltd., Chengdu Institute of Biological Products Co. Ltd., Wuhan Institute of Biological Products Co. Ltd., Eubiologics Co. Ltd., Incepta Vaccine Limited, GC Pharma, KM Biologics Inc., Bharat Immunologicals and Biologicals Corporation Limited, Sinovac Biotech Ltd., Bio Farma Indonesia

Get The Full Typhoid Vi Polysaccharide Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Which Region Accounts For The Largest Portion Of The Typhoid Vi Polysaccharide Vaccine Market?

Asia-Pacific was the largest region in the typhoid Vi polysaccharide vaccine market share in 2025. The regions covered in the typhoid vi polysaccharide vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Typhoid Vi Polysaccharide Vaccine Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/typhoid-vi-polysaccharide-vaccine-global-market-report

Browse Through More Reports Similar to the Global Typhoid Vi Polysaccharide Vaccine Market 2026, By The Business Research Company

Preventive Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/preventive-vaccines-global-market-report

Vaccines Market Report

https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report

Chickenpox Vaccine Market Report

https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795